Starting with Rosuvastatin in Primary Hyperlipidemia—

Abstract

The authors investigated the effects of rosuvastatin, beyond its lipid-lowering activity, on several nonlipid metabolic variables, along with its safety and tolerability, in patients treated for primary hyperlipidemia. Patients (n = 55) with primary hyperlipidemia were open-label assigned to the recommended starting dose of rosuvastatin 10 mg/day, and serum metabolic variables were measured at baseline and after 8 and 20 weeks. Treatment with rosuvastatin produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, nonhigh-density lipoprotein cholesterol (non HDL-C), and triglyceride concentrations, whereas HDL-C, apolipoprotein A-I, and lipoprotein(a) levels did not change significantly from baseline. The LDL-C treatment target was achieved in 71% of patients. No significant variations in renal function parameters (serum creatinine and creatinine clearance), insulin resistance estimates, and serum concentrations of uric acid, total homocysteine, vitamin B12, and folic acid were observed during the period of treatment. High-sensitivity C-reactive protein levels were significantly lowered by rosuvastatin therapy (median values, 3.1 vs 2.0 vs 1.9 mg/L, at 0, 8, and 20 weeks, respectively; p < 0.0001). In conclusion, rosuvastatin at 10 mg/day is a highly effective, safe, and well-tolerated monotherapy option for patients with primary hyperlipidemia, with a favorable antiinflammatory potential and nondeteriorating effects on renal function.

Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study

“…With respect to their impact on IS, previous reports of rosuvastatin showed no effect (15)(16)(17) or even worsening of IR (18). Atorvastatin was neutral in our study which is consistent with most previous reports (8,19), although some demonstrated amelioration (20) or worsening of IR (21).…”

Effects of Rosuvastatin With or Without Ezetimibe on Clinical Outcomes in Patients Undergoing Elective Vascular Surgery

“…The RSV was selected due to its anticipated significant absolute LDL cholesterol reduction and the favorable safety profile with the starting dose of 10 mg/d. 12 The addition of ezetimibe to the statin was decided because it is well documented that this combination reduces LDL cholesterol by the equivalent of around 3 doublings of the statin dose. 13 All patients were preoperatively screened in accordance with the recommendations proposed by the American Heart Association/American College of Cardiology Task Force.…”

An Overview of the Extra-Lipid Effects of Rosuvastatin

“…However, no influence on renal function parameters (creatinine, eGFR) has been shown in patients with primary hyperlipidemia receiving rosuvastatin 10 to 20 mg/day for 12 to 20 weeks of therapy. 44,45,115,116 Rosuvastatin and renoprotection: a mechanistic approach. Potential mechanisms that could explain the "renoprotective" actions of rosuvastatin include immunomodulatory properties, regulation of endothelial function, tissue protective and antioxidant properties, as well as beneficial effects on renal hemodynamics.…”